EUVIMEDEUVIMED entdecken
Crossref

Identification of Sulfonamide‐Based Thiazolidine‐2,4‐Dione Derivatives as VEGFR‐2 and Tumor‐Associated hCA IX Inhibitors With Hypoxia‐Targeted Anti‐Colorectal Cancer Activity

Haytham O Tawfik iD, Mohammed A Dahab iD, Mohamed R Elnagar iD, Andrea Ammara iD, Mahmoud S Elkotamy iD, Maha-Hamadien Abdulla iD, Khayal Al-Khayal iD, Mohamed Fares iD, Alessio Nocentini iD, Claudiu T Supuran iD, Wagdy M Eldehna iD

Drug Development Research · 2026

DOI: 10.1002/ddr.70333 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2026. Verfasst von Haytham O Tawfik und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, Tanta, Egypt. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, Carbonic Anhydrase IX, Sulfonamides, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: King Saud University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Given their critical roles in tumor progression and hypoxia adaptation, concurrent inhibition of carbonic anhydrase IX (hCA IX) and vascular endothelial growth factor receptor‐2 (VEGFR‐2) is a viable therapeutic approach. This study rationally developed, synthesized, and biologically assessed a novel class of thiazolidinedione‐benzenesulfonamide hybrids as possible dual hCA IX/VEGFR‐2 inhibitors. A number of agents, including 4a , 4b , 4e , 4g , 6a , and 6b , showed strong hCA IX inhibition ( K I = 15.0–37.9 nM), outperforming the reference inhibitor acetazolamide ( K I = 25 nM) and displaying better selectivity indices. Moreover, these substances efficiently suppressed VEGFR‐2, with IC 50 values ranging from 0.055 to 1.080 µM. Under both normoxic and hypoxic conditions, biological evaluation demonstrated strong anti‐proliferative activity against colorectal cancer cell lines (HT‐29 and HCT‐116). Compound 4g stood out as the most promising candidate among the investigated derivatives, showing greater activity to 5‐fluorouracil during hypoxia and comparable potency under normoxia (IC 50 = 5.89 vs. 26.66 µM). In hypoxic conditions, 4g significantly enhanced the cytotoxicity of 5‐fluorouracil, increasing its activity by more than sevenfold. 4g caused cell‐cycle arrest at the G 1 /G 2 /M phases, raised pro‐apoptotic markers (caspase‐3, caspase‐9, and BAX), downregulated the anti‐apoptotic protein Bcl‐2, and dramatically enhanced apoptotic cell death (total apoptosis: 37.78%), according to mechanistic studies. The persistent binding of 4g inside the zinc‐containing active site of hCA IX and the ATP‐binding pocket of VEGFR‐2 was validated by molecular docking and molecular dynamics simulations. Additionally, favorable pharmacokinetic and drug‐likeness features were shown by in silico ADME research. All of these results point to compound 4g as a promising mechanism‐based dual VEGFR‐2/hCA IX inhibitor with strong anti‐colorectal cancer action, especially in hypoxic tumor microenvironment circumstances.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vascular Endothelial Growth Factor Receptor-2Carbonic Anhydrase IXSulfonamidesAntineoplastic AgentsThiazolidinedionesColorectal NeoplasmsCarbonic Anhydrase InhibitorsHumansMolecular Docking SimulationCell ProliferationHCT116 CellsApoptosisHT29 CellsCell Line, TumorAntigens, NeoplasmCell HypoxiaBenzenesulfonamides

Stichwörter der Autor:innen

In silicoThiazolidinedioneVEGFR‐2adjuvant therapyapoptosishCA IX

Substanzen

Vascular Endothelial Growth Factor Receptor-2Carbonic Anhydrase IXSulfonamidesAntineoplastic AgentsThiazolidinedionesCA9 protein, humanCarbonic Anhydrase InhibitorsKDR protein, humanAntigens, NeoplasmBenzenesulfonamides

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alsalam University, Tanta, Egypt.
  • Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt.
  • Department of Pharmacology, College of Pharmacy, The Islamic University, Najaf, Iraq.
  • Department of NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Polo Scientifico, Firenze, Sesto Fiorentino, Italy.

ORCID-Profile: Haytham O Tawfik, Mohammed A Dahab, Mohamed R Elnagar, Andrea Ammara, Mahmoud S Elkotamy, Maha-Hamadien Abdulla, Khayal Al-Khayal, Mohamed Fares, Alessio Nocentini, Claudiu T Supuran, Wagdy M Eldehna

Förderung

  • King Saud University

Zitieren

APA

Tawfik, H. O., Dahab, M. A., Elnagar, M. R., Ammara, A., Elkotamy, M. S., Abdulla, M. H., Al-Khayal, K., Fares, M., Nocentini, A., Supuran, C. T., & Eldehna, W. M. (2026). Identification of Sulfonamide‐Based Thiazolidine‐2,4‐Dione Derivatives as VEGFR‐2 and Tumor‐Associated hCA IX Inhibitors With Hypoxia‐Targeted Anti‐Colorectal Cancer Activity. Drug Development Research. https://doi.org/10.1002/ddr.70333

Vancouver

Tawfik HO, Dahab MA, Elnagar MR, Ammara A, Elkotamy MS, Abdulla MH, et al. Identification of Sulfonamide‐Based Thiazolidine‐2,4‐Dione Derivatives as VEGFR‐2 and Tumor‐Associated hCA IX Inhibitors With Hypoxia‐Targeted Anti‐Colorectal Cancer Activity. Drug Development Research. 2026. doi:10.1002/ddr.70333

BibTeX
@article{Tawfik2026,
  author = {Tawfik, Haytham O and Dahab, Mohammed A and Elnagar, Mohamed R and Ammara, Andrea and Elkotamy, Mahmoud S and Abdulla, Maha-Hamadien and Al-Khayal, Khayal and Fares, Mohamed and Nocentini, Alessio and Supuran, Claudiu T and Eldehna, Wagdy M},
  title = {Identification of Sulfonamide‐Based Thiazolidine‐2,4‐Dione Derivatives as VEGFR‐2 and Tumor‐Associated hCA IX Inhibitors With Hypoxia‐Targeted Anti‐Colorectal Cancer Activity},
  journal = {Drug Development Research},
  year = {2026},
  doi = {10.1002/ddr.70333}
}
Kostenlos starten →